Digitisation | August 19, 2022
QPharma launches Ti OrderPoint 2
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.
Company appoints five new independent directors to reconstituted board
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022
The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Subscribe To Our Newsletter & Stay Updated
